Class information for:
Level 1: ANTIANGIOGENIC CANCER VACCINE//CELL PROTEOMIC FOOTPRINTING//HER1 VACCINE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
32165 112 41.7 86%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
151 22214 IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 ANTIANGIOGENIC CANCER VACCINE Author keyword 4 75% 3% 3
2 CELL PROTEOMIC FOOTPRINTING Author keyword 2 67% 2% 2
3 HER1 VACCINE Author keyword 1 100% 2% 2
4 CELL SURFACE PROFILING Author keyword 1 40% 2% 2
5 E INTERNAL MED TRADIT CHINESE MED Address 1 40% 2% 2
6 SELF IMMUNIZATION Author keyword 1 33% 2% 2
7 TRADIT CHINESE MED ONCOL Address 1 21% 3% 3
8 2MHSP70407 426 Author keyword 1 50% 1% 1
9 BIOMED CANC UK ANGIOGENESIS GRP Address 1 50% 1% 1
10 CANCER CELL VACCINE Author keyword 1 50% 1% 1

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class		 LCSH search Wikipedia search
1 ANTIANGIOGENIC CANCER VACCINE 4 75% 3% 3 Search ANTIANGIOGENIC+CANCER+VACCINE Search ANTIANGIOGENIC+CANCER+VACCINE
2 CELL PROTEOMIC FOOTPRINTING 2 67% 2% 2 Search CELL+PROTEOMIC+FOOTPRINTING Search CELL+PROTEOMIC+FOOTPRINTING
3 HER1 VACCINE 1 100% 2% 2 Search HER1+VACCINE Search HER1+VACCINE
4 CELL SURFACE PROFILING 1 40% 2% 2 Search CELL+SURFACE+PROFILING Search CELL+SURFACE+PROFILING
5 SELF IMMUNIZATION 1 33% 2% 2 Search SELF+IMMUNIZATION Search SELF+IMMUNIZATION
6 2MHSP70407 426 1 50% 1% 1 Search 2MHSP70407+426 Search 2MHSP70407+426
7 CANCER CELL VACCINE 1 50% 1% 1 Search CANCER+CELL+VACCINE Search CANCER+CELL+VACCINE
8 CELLULAR CANCER VACCINE 1 50% 1% 1 Search CELLULAR+CANCER+VACCINE Search CELLULAR+CANCER+VACCINE
9 HEPATOCELLULAR CARCINOMA IMMUNOTHERAPY 1 50% 1% 1 Search HEPATOCELLULAR+CARCINOMA+IMMUNOTHERAPY Search HEPATOCELLULAR+CARCINOMA+IMMUNOTHERAPY
10 MANNAN RECEPTOR 1 50% 1% 1 Search MANNAN+RECEPTOR Search MANNAN+RECEPTOR

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 IMMUNOGENE THERAPY 3 22% 12% 13
2 EFFECTIVE ADJUVANT 1 17% 4% 5
3 INHIBITS TUMOR ANGIOGENESIS 1 16% 4% 4
4 PLATELET GPIIB IIIA ANTAGONISTS 1 50% 1% 1
5 RECOMBINANT XENOGENEIC ENDOGLIN 1 20% 3% 3
6 SYNERGISTIC ANTITUMOR ACTIVITIES 1 25% 2% 2
7 MODEL ANTIGEN 0 20% 2% 2
8 DEPENDENT TUMOR 0 25% 1% 1
9 ANTIANGIOGENIC CANCER THERAPY 0 17% 1% 1
10 COPOLYMERIC NANOPARTICLES 0 14% 1% 1

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy 2006 22 53 30%
Anti-angiogenic active immunotherapy: a new approach to cancer treatment 2008 6 46 28%
Potential influence of international harmonization of pharmaceutical regulations on biopharmaceutical development 1997 4 2 50%
Vaccination approach to anti-angiogenic treatment of cancer 2015 0 127 23%
Tumor Stroma as a Target in Cancer 2008 23 71 7%
Vaccination against angiogenesis-associated antigens: A novel cancer immunotherapy strategy 2003 7 26 27%
Cancer Immunotherapy of Targeting Angiogenesis 2004 5 43 19%
Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins 2013 2 27 7%
Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens 2010 4 63 13%
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma 2008 5 133 9%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 E INTERNAL MED TRADIT CHINESE MED 1 40% 1.8% 2
2 TRADIT CHINESE MED ONCOL 1 21% 2.7% 3
3 BIOMED CANC UK ANGIOGENESIS GRP 1 50% 0.9% 1
4 IMMUN INFECT CANC STUDIES 1 50% 0.9% 1
5 ONCOL DNA MED 1 50% 0.9% 1
6 BIOTHER Y HUMAN DIS 1 13% 4.5% 5
7 SYST BIOL DIRECT 0 33% 0.9% 1
8 DEV DIRECT 0 18% 1.8% 2
9 BIOTHER Y CANC 0 10% 2.7% 3
10 GD SEARLE DEV 0 25% 0.9% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000239023 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
2 0.0000191325 NEUGCGM3//N GLYCOLYL GM3//CMP N ACETYLNEURAMINIC ACID HYDROXYLASE
3 0.0000186149 ENDOSIALIN//CD248//TEM1
4 0.0000137285 ACUTE REJECTION REACTION//TUMOR ANGIOGENESIS//E S 8
5 0.0000126613 FLT 1//VEGF RECEPTORS//VEGF165B
6 0.0000124083 BELAGENPUMATUCEL L//SRL172//PA MSHA
7 0.0000121389 ENDOGLIN//CD105//TRC105
8 0.0000118998 CCDC134//TUMOR IMMUN TOLERANCE SECT//ANTIGEN SPECIFIC CTL FUNCTION
9 0.0000114760 CANC VACCINE DEV PROGRAM//CANC SECT//ONCOANTIGENS
10 0.0000109478 ENDOSTATIN//ANGIOSTATIN//COLLAGEN XVIII